Literature DB >> 18769352

Total lymphocyte count: not a surrogate marker for risk of death in HIV-infected Ugandan children.

Philippa M Musoke1, Alicia M Young, Maxensia A Owor, Irene R Lubega, Elizabeth R Brown, Francis A Mmiro, Lynne M Mofenson, J Brooks Jackson, Mary Glenn Fowler, Laura A Guay.   

Abstract

OBJECTIVES: To determine the utility of total lymphocyte count (TLC) in predicting the 12-month mortality in HIV-infected Ugandan children and to correlate TLC and CD4 cell %.
DESIGN: This is a retrospective data analysis of clinical and laboratory data collected prospectively on 128 HIV-infected children in the HIV Network for Prevention Trials 012 trial.
METHODS: TLC and CD4 cell % measurements were obtained at birth, 14 weeks, and 12, 24, 36, 48, and 60 months of age and assessed with respect to risk of death within 12 months.
RESULTS: Median TLC per microliter (CD4 cell %) was 4150 (41%) at birth, 4900 (24%) at 12 months, 4300 (19%) at 24 months, 4150 (19%) at 36 months, 4100 (18%) at 48 months, and 3800 (20%) at 60 months. The highest risk of mortality within 12 months was 34% - 37% at birth and declined to 13%-15% at 24 months regardless of TLC measurement. The correlation between CD4 cell % and TLC was extremely low overall (r = 0.01).
CONCLUSIONS: The TLC did not predict a risk of progression to death within 12 months in HIV-infected Ugandan children. Therefore, TLC alone may not be a useful surrogate marker for determining those children at highest risk of death, who require antiretroviral therapy most urgently.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18769352      PMCID: PMC2721476          DOI: 10.1097/QAI.0b013e318183a92a

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  26 in total

1.  Time-dependent ROC curves for censored survival data and a diagnostic marker.

Authors:  P J Heagerty; T Lumley; M S Pepe
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

2.  Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings.

Authors:  Motasim Badri; Robin Wood
Journal:  AIDS       Date:  2003-03-07       Impact factor: 4.177

3.  Morbidity among human immunodeficiency virus-1-infected and -uninfected African children.

Authors:  T E Taha; S M Graham; N I Kumwenda; R L Broadhead; D R Hoover; D Markakis; L van Der Hoeven; G N Liomba; J D Chiphangwi; P G Miotti
Journal:  Pediatrics       Date:  2000-12       Impact factor: 7.124

4.  Maternal and infant factors predicting disease progression in human immunodeficiency virus type 1-infected infants. Women and Infants Transmission Study Group.

Authors:  K C Rich; M G Fowler; L M Mofenson; R Abboud; J Pitt; C Diaz; I C Hanson; E Cooper; H Mendez
Journal:  Pediatrics       Date:  2000-01       Impact factor: 7.124

5.  Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians.

Authors:  Yared Mekonnen; Nicole H Dukers; Eduard Sanders; Wendelien Dorigo; Dawit Wolday; Ab Schaap; Ronald B Geskus; Roel A Coutinho; Arnaud Fontanet
Journal:  AIDS       Date:  2003-04-11       Impact factor: 4.177

6.  HIV-1 ICD p24 antigen detection in ugandan infants: use in early diagnosis of infection and as a marker of disease progression.

Authors:  L A Guay; D L Hom; S R Kabengera; E M Piwowar-Manning; P Kataaha; C Ndugwa; L H Marum; I Kalyesubula; J B Jackson
Journal:  J Med Virol       Date:  2000-12       Impact factor: 2.327

7.  Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings.

Authors:  Lisa A Spacek; Michael Griswold; Thomas C Quinn; Richard D Moore
Journal:  AIDS       Date:  2003-06-13       Impact factor: 4.177

8.  Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries.

Authors:  N Kumarasamy; Anish P Mahajan; Timothy P Flanigan; R Hemalatha; Kenneth H Mayer; Charles C J Carpenter; S P Thyagarajan; Suniti Solomon
Journal:  J Acquir Immune Defic Syndr       Date:  2002-12-01       Impact factor: 3.731

9.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.

Authors:  J Brooks Jackson; Philippa Musoke; Thomas Fleming; Laura A Guay; Danstan Bagenda; Melissa Allen; Clemensia Nakabiito; Joseph Sherman; Paul Bakaki; Maxensia Owor; Constance Ducar; Martina Deseyve; Anthony Mwatha; Lynda Emel; Corey Duefield; Mark Mirochnick; Mary Glenn Fowler; Lynne Mofenson; Paolo Miotti; Maria Gigliotti; Dorothy Bray; Francis Mmiro
Journal:  Lancet       Date:  2003-09-13       Impact factor: 79.321

10.  Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data.

Authors: 
Journal:  Lancet       Date:  2005-11-26       Impact factor: 79.321

View more
  2 in total

1.  Prognosis of children with HIV-1 infection starting antiretroviral therapy in Southern Africa: a collaborative analysis of treatment programs.

Authors:  Mary-Ann Davies; Margaret May; Carolyn Bolton-Moore; Cleophas Chimbetete; Brian Eley; Daniela Garone; Janet Giddy; Harry Moultrie; James Ndirangu; Sam Phiri; Helena Rabie; Karl-Günter Technau; Robin Wood; Andrew Boulle; Matthias Egger; Olivia Keiser
Journal:  Pediatr Infect Dis J       Date:  2014-06       Impact factor: 2.129

2.  Utility of total lymphocyte count as a surrogate marker for CD4 counts in HIV-1 infected children in Kenya.

Authors:  Nyawira Githinji; Elizabeth Maleche-Obimbo; Moses Nderitu; Dalton C Wamalwa; Dorothy Mbori-Ngacha
Journal:  BMC Infect Dis       Date:  2011-09-30       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.